Table 1. Binding stability of tralokinumab and lebrikizumab with IL-13.

	Rosetta’s energy score (REU)		Total energy (kcal/mol)
	complex with IL-13R144	complex with IL-13Q144	complex with IL-13R144	complex with IL-13Q144
tralokinumab	-1522.531	-1549.034	-219.950	-276.692
lebrikizumab	-2122.571	-2158.778	-110.031	-178.468

IL-13R144, wild type of IL-13, which contains arginine (R) at position 144 of the IL-13 protein. IL-13Q144, executes a non-conservative replacement of a positively charged arginine (R) with a neutral glutamine (Q) at position 144 of the IL-13 protein.